Global Renal Biomarker Market, By End-User (Hospitals, Diagnostic Laboratories, Other), Marker Type (Creatinine, Blood Urea Nitrogen (BUN), Cystatin C, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Others), Assay Platform Type (Enzyme Linked Immunosorbent Assay (ELISA), Enzymatic Assay, Turbidimetric Immunoassay, Others) Application (Diagnosis and Disease Progression Monitoring, Research) – Industry Trends and Forecast to 2029
Market Analysis and Size
Over the last decade, advances in genetic technology have increased people's understanding of genetic regulatory pathways related to renal biomarkers. Genetics analysis has become essential in clinical practice and research due to rapid advances in genomic technologies. Furthermore, as computer technology has advanced, renal biomarkers testing has become more widely available and feasible to perform, even in small-scale laboratories. Recent genetic advances have made it possible to study kidney disease in a variety of platforms, including human populations.
Data Bridge Market Research analyses that the renal biomarker market is expected to reach the value of USD 508.34 million by the year 2029, at a CAGR of 7.70% during the forecast period. The renal biomarker market is being driven by an increase in the incidence of kidney-related diseases as well as an increase in biomarker approval.
Market Definition
Renal biomarkers are primarily used to treat renal diseases. It is used to examine the function of the renal system, and these biomarkers are useful in both research and clinical settings.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By End-User (Hospitals, Diagnostic Laboratories, Other), Marker Type (Creatinine, Blood Urea Nitrogen (BUN), Cystatin C, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Others), Assay Platform Type (Enzyme Linked Immunosorbent Assay (ELISA), Enzymatic Assay, Turbidimetric Immunoassay, Others) Application (Diagnosis and Disease Progression Monitoring, Research
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.)
|
|
|
|
|
Opportunities
|
|
|
|
|
|
|
|
Renal biomarker Market Dynamics
Drivers
- The rise in the geriatric and paediatric renal patients
Rise in geriatric and paediatric renal disease patients is a critical factor driving market growth, as is an increase in government support, technological advancement in the field of genetics, rise in the prevalence rate of CKD, and high presence and knowledge of serum creatinine biomarkers driving market growth, among other factors driving the renal biomarket.
- The rise in the technological advancement
Technological advancements and modernization in healthcare techniques, as well as an increase in demand from emerging economies, will create new opportunities for the renal biomarker market during the forecasted period
- Government investments for healthcare interoperability
The increase in the funding by the federal government to drive the adoption of these solutions further influence the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the renal biomarker market.
.Restraints/Challenges
However, problems with regulatory and reimbursement systems are among the major factors that will obstruct market growth and will further challenge the growth of the renal biomarker market during the forecast period.
This renal biomarker market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the renal biomarker market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Renal Biomarker Market Scope
The renal biomarker market is segmented on the basis end-user, marker type, assay platform type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
End user
- Hospitals
- diagnostic laboratories
- Other
On the basis of end-user, renal biomarker market is segmented into hospitals, diagnostic laboratories and other.
Marker type
- Creatinine
- Blood urea nitrogen (bun)
- Cystatin c
- Neutrophil gelatinase-associated lipocalin (NGAL)
- Others
Based on marker type, the renal biomarker market is segmented into Creatinine, blood urea nitrogen (bun), cystatin c, neutrophil gelatinase-associated lipocalin (NGAL) and others.
Assay platform type
- Enzyme linked immunosorbent assay (ELISA)
- Enzymatic assay
- Turbidimetric immunoassay
- Others
Based on assay platform type, the renal biomarker market is segmented into enzyme linked immunosorbent assay (elisa), enzymatic assay, turbidimetric immunoassay and others.
Application
- Diagnosis and disease progression monitoring
- Research homecare
The renal biomarker market is also segmented on the basis of application into diagnosis and disease progression monitoring and research.
Renal Biomarker Market Regional Analysis/Insights
The renal biomarker market is analysed and market size insights and trends are provided by country, end-user, marker type, assay platform type and application as referenced above.
The countries covered in the renal biomarker market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the renal biomarker market due to increased government support, technological advancement in the field of genetics, an increase in the prevalence rate of CKD, and the region's high presence and knowledge of serum creatinine biomarkers. Europe is the expected region for growth in the renal biomarker market due to increased government support and technological advancement in the field of genetics in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The renal biomarker market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for renal biomarker market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the renal biomarker market. The data is available for historic period 2010-2020.
Competitive Landscape and Renal Biomarker Market Share Analysis
The renal biomarker market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to renal biomarker market.
Some of the major players operating in the renal biomarker market are
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- AbbVie Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- Merck KGaA (Germany)
- LEO Pharma A/S (Denmark)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Fresenius Kabi AG (Germany)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-